Identifying blood markers to predict treatment response in children with neuroblastoma
Circulating biomarkers of clinical response to combination targeted therapies in neuroblastoma
This study is looking at how certain blood tests can help doctors understand which new treatments work best for kids with advanced neuroblastoma, making it easier and safer for them by using simple blood samples instead of more invasive tests.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11061047 on NIH RePORTER |
What this research studies
This research investigates how specific blood markers can help predict how well children with advanced neuroblastoma will respond to new combination therapies. By analyzing samples from a clinical trial, researchers will look for circulating tumor DNA and cells that may indicate treatment effectiveness. This approach aims to minimize invasive procedures by using liquid biopsies, making it safer for young patients. The study will compare different treatment combinations to find the most effective options for these children.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years diagnosed with advanced neuroblastoma who are eligible for the clinical trial.
Not a fit: Patients with neuroblastoma who are not eligible for the trial or those with early-stage disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for children with neuroblastoma.
How similar studies have performed: Previous studies have shown promise in using circulating biomarkers for treatment response in various cancers, indicating a potential for success in this novel approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Vo, Kieuhoa Tran — University of California, San Francisco
- Study coordinator: Vo, Kieuhoa Tran
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.